Liver Damaging Supplements: Are the everyday supplements damaging the liver? Experts weigh in
We take numerous supplements daily. From the ones that enhance workout performance to those that boost skin and hair health, the supplements industry is booming. But are those supplements you take for added benefits putting your liver at risk? A recent study suggests that the herbal and dietary supplements that people take every day may pose a risk to liver health.
Tired of too many ads? go ad free now
A study from the University of Michigan found that several supplements contain potentially hepatotoxic botanical ingredients. The findings are published in
. The researchers analyzed data from the National Health and Nutrition Examination Survey collected between 2017 and 2020. They found that 4.7% of US adults reported using herbal and dietary supplements containing at least one of the botanicals of interest: turmeric; green tea; ashwagandha; black cohosh; garcinia cambogia; and red yeast rice containing products.
'Our interest started when we saw cases of liver toxicity from herbal and dietary supplement use in people enrolled in the ongoing NIH-funded DILIN study. But it was difficult to say how many people were using these supplements and why. The major finding here is the large number of Americans taking these products, with an estimated 15 million adult Americans taking them on a regular basis,' Alisa Likhitsup, clinical assistant professor of Medicine at U-M and lead author, said in a statement.
(Pic courtesy: iStock)
Previous research has found the specific botanicals studied as potentially hepatotoxic. The recent study looks at the longstanding concerns about the supplement industry, such as a lack of government regulation, insufficient attention in medical screenings, and frequent
.
'In a previous study, we found that there was a great deal of mislabeling of some of these products. We performed analytical chemistry and found about a 50% mismatch between stated ingredients on the label and what they actually contained, which is quite alarming.
Tired of too many ads? go ad free now
If you buy a supplement and it says it has a certain ingredient, it's basically a coin flip if that's true or not,' Robert Fontana, Michigan Medicine hepatologist, professor of medicine, and senior author, said.
Due to a lack of regulation, there was mislabeling, and since their effects are not well understood, clinicians often will not ask patients what supplements they are taking.
'We weren't aware that so many people were taking these supplements.
So, when doctors see patients in the office, they don't necessarily ask about supplement use or take into consideration their effects,' Likhitsup, a transplant hepatologist, noted.
In the participants, the highest proportion of people consumed turmeric (3.46%), followed by green tea (1.01%), ashwagandha and black cohosh (0.38%), garcinia cambogia (0.27%), and red yeast rice products (0.19%). They took the supplements on their own and not on the advice of a doctor.
They consumed the supplements to improve or maintain health.
Of the turmeric users, 26.8% consumed the products specifically for supposed benefits for joint health or arthritis, while 27.2% of the green tea users were hoping to improve their energy levels. The majority of the garcinia cambogia users hoped it would help them lose weight.
Top Supplements for Men's Health Over 30
A study hinted that there was a 70% increase in liver transplants due to injury caused by supplements from 2010-2020, compared to 1994-2009. Though the new study wasn't able to establish any kind of causal relationship between consumption of the six botanicals and liver injury, the researchers still hope to make clinicians and patients aware of just how much is still unknown about these supplements.
'We're not trying to create an alarm. We're just trying to increase awareness that the over-the-counter supplements people are taking and buying have not been tested nor necessarily proven to be safe,' Fontana said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
2 hours ago
- Mint
These diabetes drugs are finding new life as an antiaging hack
Some health-obsessed Americans believe the next antiaging therapeutic already exists—in the medicine cabinets of millions of diabetes patients. The widely used class of drugs, called SGLT2 inhibitors and sold under brand names such as Jardiance and Farxiga, have been on the market for over a decade as Type 2 diabetes medications. They have also gained regulatory approval to treat conditions like heart failure and kidney disease. Recently, though, the drugs have emerged as a hot topic on popular health podcasts and Reddit forums for longevity enthusiasts, many of whom don't suffer from any of those conditions. Instead, they are adding SGLT2 inhibitors to a roster of hacks they hope will help them live healthier for longer—or in other words, increase their healthspan. The drugs work by helping the kidneys release extra glucose from the body through urine, improving blood-sugar levels. While there are no studies of whether they can extend the lives of healthy humans, a growing body of evidence shows they help protect against multiple age-related diseases and reduce mortality rates for patients with certain chronic conditions. Some researchers believe they may also affect the fundamental biology of aging. 'This is probably the drug class of our era," says Dr. Timothy Gong, section physician leader for heart failure and transplant cardiology at Baylor University Medical Center, who has researched SGLT2 inhibitors. 'You see cardiologists, nephrologists, endocrinologists, even general internists as well, just getting so excited." Gong says he wouldn't be surprised to take an SGLT2 inhibitor one day, once they are studied more, though he's free from heart issues and diabetes. Yet it's too early to prescribe it for longevity benefits in otherwise healthy patients. 'I don't think that the evidence is strong enough yet for us to be able to say that," he says. Right now, use of SGLT2 inhibitors for potential antiaging benefits is limited mostly to a growing community of so-called biohackers, who seek to optimize their health through experimentation with gadgets, behaviors and various medicines and supplements. Because most take it off-label—meaning, for a nonapproved use—the drugs typically aren't covered by insurance and can cost hundreds of dollars a month out of pocket. Dave Aiello, a Boston chiropractor who doesn't have diabetes, began experimenting with the drugs after learning about a promising study in mice. The 38-year-old wanted to get ahead of health problems but was disenchanted by what he saw as a reactive approach to disease in conventional medicine. 'I'm trying to see if I can just stay as healthy as possible for as long as possible," says Aiello, who has been taking an SGLT2 inhibitor called empagliflozin since 2022. He also takes the kidney-transplant drug rapamycin off-label and has previously taken the diabetes pill metformin—both of which have gained traction as potential longevity boosters, too. He was particularly impressed by research showing SGLT2 inhibitors can help the body manage blood sugar more efficiently, which in turn supports cardiometabolic health. He says he's encouraged by the results so far: Between 2022 and 2024, Aiello's hemoglobin A1C, a measure of average blood sugar, fell to 4.6% from 5.1%, his laboratory test results show. The drugs aren't free of potential side effects, including increased risk of urinary-tract infections, dehydration, and in rare cases, severe genital infections and a life-threatening condition called diabetic ketoacidosis. When Aiello first started taking empagliflozin, he felt dehydrated and experienced fatigue and brain fog. Those side effects have subsided since he decreased his dose and has made sure to take in more electrolytes. 'I'm a little more willing to take some risks that could potentially affect me in the short term if I do think that there might be a benefit," Aiello says. It isn't clear precisely how SGLT2 inhibitors might protect against the ravages of aging, but the research in mice offers clues. In 2020, a National Institute on Aging-funded study found that one SGLT2 inhibitor called canagliflozin extended the lives of male—but not female—mice by 14%. One theory is that the drugs help slow the aging process partly by blunting blood-sugar spikes. Scientists say that by driving insulin levels down, these drugs promote fat burning and create an anti-inflammatory effect that mimics calorie restriction, which studies suggest can slow the pace of aging. Still, many drugs that work in mice don't work in humans, says Richard A. Miller, who led the study and is director of the Glenn Center for Biology of Aging Research at the University of Michigan. His lab is now studying how the small molecules inside slow-aging mice change over time. If a drug in humans produces these same metabolomic shifts seen in slow-aging mice, he says, it would provide more confidence that it could slow aging in people. 'We still have a lot of work to do to prove that the drugs do the same thing in people," says Miller. 'The hint here is that it's actually slowing the aging rate." Alan Vuong, who works in sales in Austin, Texas, started taking the SGLT2 inhibitor dapagliflozin this year after hearing a podcast interview with Miller. The 34-year-old has a family history of Type 2 diabetes and wanted to lower his fasting insulin level, a measure of metabolic health, from normal to optimal. He spends about $150 a month on his longevity protocol, which includes a dozen drugs and supplements, and has seen his insulin levels drop since starting the medication. Other than having to use the bathroom in the middle of the night more often, a known side effect of the drugs, Vuong hasn't noticed other physical side effects. 'My end goal is to extend lifespan, but more importantly, healthspan," he says. 'I'm willing to take that gamble."
Economic Times
11 hours ago
- Economic Times
This is why nearly 700,000 Americans lost Medicaid coverage in one month
Enrollment Declines Sharply End of Pandemic Policies Triggers Losses Administrative Issues Lead to Disenrollments Live Events Millions Disenrolled Mixed Outcomes State-Level Reductions Vary FAQs (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel New federal data reveals that nearly 700,000 Americans were removed from Medicaid in January 2025. The figures, compiled by KFF, show the ongoing impact of the federal Medicaid unwinding process. This change followed the end of COVID-19 emergency to KFF, Medicaid enrollment dropped by 669,938 between December 2024 and January 2025. This brought the total number of Medicaid enrollees to about 71.2 million. Although still above February 2020 levels, this marks a significant monthly decline in the COVID-19 public health emergency, many protections were added to Medicaid. These protections paused eligibility reviews and extended coverage for many people. When these measures ended, states resumed redetermination checks to verify if people still qualified for people lost coverage not because they no longer qualified but due to missed deadlines, paperwork errors, or out-of-date contact details. Health experts say many are falling out of the system due to communication problems and not being aware of what is needed to keep their the unwinding began in spring 2023, more than 16 million people have been removed from Medicaid. The monthly drops reflect a steady trend that began once states resumed checking eligibility. Many are still at risk of losing coverage if they do not meet the updated requirements or face administrative issues.A KFF survey in April 2024 found that among those who lost Medicaid before April 1, 2023, about 47 percent were re-enrolled. Another 28 percent found other forms of coverage. About one in four reported being uninsured after losing states have seen sharper drops in enrollment. In Montana, Tennessee, and Colorado, January 2025 figures fell below levels recorded before the pandemic began. These states have experienced faster rates of Medicaid disenrollment during the ongoing redetermination are losing coverage due to paperwork problems, communication issues, or missed deadlines, not because they no longer qualify based on income or health People who lose coverage can reapply. Some have already been re-enrolled, while others have obtained private or employer-based health plans.
Time of India
11 hours ago
- Time of India
This is why nearly 700,000 Americans lost Medicaid coverage in one month
In January 2025, almost 700,000 Americans lost Medicaid coverage, continuing a national decline that started after pandemic protections ended. The drop, part of the unwinding process, affects low-income individuals. Administrative issues, not eligibility, have led to many losing access. Total enrollment now stands at about 71.2 million. Tired of too many ads? Remove Ads Enrollment Declines Sharply End of Pandemic Policies Triggers Losses Administrative Issues Lead to Disenrollments Tired of too many ads? Remove Ads Millions Disenrolled Mixed Outcomes State-Level Reductions Vary FAQs New federal data reveals that nearly 700,000 Americans were removed from Medicaid in January 2025. The figures, compiled by KFF, show the ongoing impact of the federal Medicaid unwinding process. This change followed the end of COVID-19 emergency to KFF, Medicaid enrollment dropped by 669,938 between December 2024 and January 2025. This brought the total number of Medicaid enrollees to about 71.2 million. Although still above February 2020 levels, this marks a significant monthly decline in the COVID-19 public health emergency, many protections were added to Medicaid. These protections paused eligibility reviews and extended coverage for many people. When these measures ended, states resumed redetermination checks to verify if people still qualified for people lost coverage not because they no longer qualified but due to missed deadlines, paperwork errors, or out-of-date contact details. Health experts say many are falling out of the system due to communication problems and not being aware of what is needed to keep their the unwinding began in spring 2023, more than 16 million people have been removed from Medicaid. The monthly drops reflect a steady trend that began once states resumed checking eligibility. Many are still at risk of losing coverage if they do not meet the updated requirements or face administrative issues.A KFF survey in April 2024 found that among those who lost Medicaid before April 1, 2023, about 47 percent were re-enrolled. Another 28 percent found other forms of coverage. About one in four reported being uninsured after losing states have seen sharper drops in enrollment. In Montana, Tennessee, and Colorado, January 2025 figures fell below levels recorded before the pandemic began. These states have experienced faster rates of Medicaid disenrollment during the ongoing redetermination are losing coverage due to paperwork problems, communication issues, or missed deadlines, not because they no longer qualify based on income or health People who lose coverage can reapply. Some have already been re-enrolled, while others have obtained private or employer-based health plans.
